Gsk 2025 Full Year Results – GSK saw core operating profit jump in Q2 and won the latest round in its ongoing legal case, making the share price look even more undervalued to me. . GSK offers promising investment opportunities in healthcare industry despite economic uncertainties and risks. Read more on GSK stock here. .
Gsk 2025 Full Year Results
Source : www.gsk.com
GSK delivers 4% growth in Q2 revenue, ups full year guidance
Source : firstwordpharma.com
Events calendar | GSK
Source : www.gsk.com
EX 15.2
Source : www.sec.gov
GSK delivers strong 2025 performance and upgrades growth outlooks
Source : www.gsk.com
2025 Annual Report
Source : www.gsk.com
Annual Report 2025 | GSK
Source : www.gsk.com
GSK reports blockbuster sales RSV shot Arexvy in race vs. Pfizer
Source : www.fiercepharma.com
GSK’s experimental drug reduces asthma attacks in late stage trial
Source : qz.com
GSK nabs highly anticipated approval for RSV vaccine Arexvy
Source : www.fiercepharma.com
Gsk 2025 Full Year Results GSK delivers strong 2025 performance and upgrades growth outlooks : According to a report by KPMG, the economy of the UK is going through a combination of consumption tailwinds and falling inflation which is expected to support modest positive growth in the country . Specialty Medicines led the way with a 22% increase, bolstered by new oncology and HIV products. GSK’s overall sales were 5% ahead of consensus in the second quarter. Specialty medicines performed .